Method for treating erectile dysfunction
Macrolide compound (I) is provided for treating or preventing erectile dysfunction, which is, for example, induced by or secondary to diseases, alcoholism, aging, arterial insufficiency, venous leakage, hormonal insufficiency, drug use, surgery, chemotherapy or radiation, particularly, for preventing or treating an erectile dysfunction of mammals.
1 : A method of manufacturing a medicament for treating or preventing erectile dysfunction comprising mixing a compound of formula (I):
with a pharmaceutically acceptable vehicle or carrier.
2 : The method of claim 9 , wherein the erectile dysfunction is induced by or secondary to a disease, alcoholism, aging, arterial insufficiency, venous leakage, hormonal insufficiency, drug use, surgery, chemotherapy or radiation.
3 : The method of claim 2 , wherein the erectile dysfunction is induced by or secondary to diabetes.
4 : The method of claim 3 , wherein the diabetes is diabetic neuropathy.
5 : The method of claim 2 , wherein the erectile dysfunction is induced by or secondary to surgery.
6 : The method of claim 5 , wherein the surgery is prostate surgery.
7 : The method of claim 2 , wherein the erectile dysfunction is caused by an injury to a penile cavernous nerve.
8 : The method of claim 9 , wherein the compound of formula (I) is a stereoisomer represented by formula (Ia):
9 : A method for preventing or treating erectile dysfunction in a subject in need thereof, which comprises administering to said subject an effective amount of a composition comprising a compound of formula (1):
10 : (canceled)
11 : A medicament made by the method of claim 1 , wherein the compound of formula (I) is in a form of its pharmaceutically acceptable salt, derivative, pro-drug or solvate.
12 : A commercial package comprising a medicament made by the method of claim 1 and a written matter associated therewith, wherein the written matter states that the compound (I) can or should be used for preventing or treating erectile dysfunction.
13 : The medicament of claim 11 , wherein the compound of formula (I) is in a solvate form selected from the group consisting of a hydrate and an ethanolate.
14 : The method of claim 9 , wherein the compound of formula (I) is in a form of its pharmaceutically acceptable salt, derivative, pro-drug or solvate.
15 : The method of claim 9 , wherein the compound of formula (I) is in a solid, semisolid or liquid form.
16 : The method of claim 9 , wherein the compound of formula (I) is administered at a daily dose ranging from 0.0001-1000 mg.
17 : The method of claim 9 , wherein the compound of formula (I) is administered at a daily dose ranging from 0.001-500 mg.
18 : The method of claim 9 , wherein the compound of formula (I) is administered at a daily dose ranging from 0.01-100 mg.
19 : The method of claim 9 , wherein the compound of formula (I) is administered chronically at a daily dose ranging from about 0. 1-30 mg/kg/day.
20 : The method of claim 9 , wherein said subject is selected from the group consisting of a cow, a horse, a dog, a cat, a rat, and a human.
21 : The method of claim 9 , wherein said subject is a human.